We are thrilled to be part of the announcement at ASHG 2016, detailing the new QIAseq® cfDNA All-in-One Kit — including the market’s first bioinformatics workflow for cell-free DNA.
With this streamlined testing solution researchers can now analyze cell-free DNA quickly, conveniently, and reliably to obtain accurate and meaningful results using any major sequencing platform. Researchers who are applying liquid biopsy methods in their work with NIPT or with hereditary and rare diseases can use this solution to address NGS bottlenecks while increasing the accuracy and sensitivity of their variant identification efforts.
We are proud to be furthering the use case for liquid biopsy, and are looking forward to hearing how others are using this tool in innovative ways at ASHG. Please stop by our booth #1234, where we’ll be hosting several presentations on Wednesday and Thursday.
For more information about the launch of the QIAseq cfDNA All-in-One Kit, please read the official press release below.
Furthermore, QIAGEN unveiled an enhanced bioinformatics workflow for hereditary and rare diseases, offering unique capabilities for research using liquid biopsies in non-invasive prenatal testing (NIPT) as well as cancer biomarker discovery. QIAGEN is rolling out the solutions at the American Society of Human Genetics ASHG 2016 Annual Meeting in Vancouver.
“The new All-in-One Kit for extraction and library preparation delivers a powerful solution for researchers to maximize their discovery potential and accuracy of results from liquid biopsies, achieving breakthroughs in NGS detection of even the rarest variants. In tandem with new dedicated bioinformatics, our cfDNA kit is creating a true Sample to Insight experience for liquid biopsy analysis, efficiently delivering, accurate and meaningful results with any major sequencing platform,” said Brad Crutchfield, Senior Vice President of QIAGEN’s Life Sciences Business Area. “Also at ASHG 2016, QIAGEN Bioinformatics is introducing an enhanced analysis and interpretation workflow for identification of disease-causing variants in hereditary and rare diseases, useful in both NIPT and cancer research. NGS users are increasingly relying on QIAGEN’s growing portfolio of Sample to Insight solutions.”
The QIAseq cfDNA kit provides a complete solution, from plasma to NGS-ready libraries, to maximize cell-free DNA conversion and discovery potential for translational research using liquid biopsies. Building on proven QIAamp technology, the gold standard in cfDNA extraction, the All-in-One kit is the first kit to combine extraction and library preparation, making library prep more convenient, efficient and accurate for the demands of exome or whole genome sequencing.
QIAGEN also is unveiling its enhanced hereditary disease solution to provide a streamlined, easy-to-use analysis and interpretation workflow for NGS data from liquid biopsies. Use of small blood samples to detect disease-causing variants in circulating cfDNA offers advantages in neonatal testing or monitoring of cancer patients for translational research, but the NGS data can be difficult to analyze. QIAGEN’s bioinformatics solution enables labs to achieve more accurate detection and the highest sensitivity in identifying variants. Integrating Biomedical Genomics Workbench, Ingenuity Variant Analysis and other components, the solution addresses NGS bottlenecks and ensures that no pathogenic variant is missed.
QIAGEN will exhibit at booth #1234 during ASHG 2016, demonstrating the cfDNA Sample to Insight workflow, the enhanced hereditary disease solution and other tools. The company also will present an educational session, “Sample-to-Insight NGS Solutions: Multimodal Liquid Biopsy WGS, Trio and Family Analyses, and RNA-sequencing Analysis and Interpretation,” from 1:00 p.m. to 2:30 p.m. on Thursday October 20 in Room 13, Convention Centre East Building. For information please visit https://staging.digitalinsights.supremeclients.com.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).